Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Hodgkin Disease
  • Medical Oncology

abstract

  • The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.

publication date

  • May 2012

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 22570290

Additional Document Info

start page

  • 589

end page

  • 97

volume

  • 10

number

  • 5